摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    17
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    29.5
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

点击查看最新优质反应信息

文献信息

  • Access to Electron-Rich Arene-Fused Hexahydroquinolizinones through a Gold-Catalysis-Initiated Cascade Process
    作者:Lianzhu Liu、Liming Zhang
    DOI:10.1002/anie.201203303
    日期:2012.7.16
    Golden Cascade: With a tethered, electron‐rich arene as the internal nucleophile, a gold‐catalyzed amide cyclization to an alkyne initiates a cascade process that ends with a Ferrier rearrangement. Electron‐rich arene‐bearing hexahydroquinolizin‐2‐ones are formed in good yields and can be converted into indole alkaloids in only a few steps.
    黄金级联:以束缚的、富电子的芳烃作为内部亲核试剂,金催化的酰胺环化成炔引发级联过程,以费里尔重排结束。富含电子的芳烃六氢喹啉-2-酮以良好的产率形成,只需几步即可转化为吲哚生物碱。
  • Substituted hexahydroarylquinolizines
    申请人:Merck & Co., Inc.
    公开号:EP0259092A1
    公开(公告)日:1988-03-09
    Certain substituted hexahydroarylquinoli­zines and pharmaceutically acceptable salts thereof are peripherally selective α₂-adrenoceptor antagonists. The compounds are adapted to be employed for the treatment of certain pathological disorders such as hypertension, diabetes, disorders involving platelet aggregation and the like without side effects attributable to effect on the central nervous system.
    某些取代的六氢芳基喹嗪类化合物及其药学上可接受的盐类是外周选择性 α₂-肾上腺素受体拮抗剂。这些化合物可用于治疗某些病理紊乱,如高血压、糖尿病、血小板聚集紊乱等,且不会对中枢神经系统产生副作用。
  • BENZOQUINOLIZINE DERIVATIVES AND MEDICINAL COMPOSITIONS
    申请人:NIPPON SHINYAKU COMPANY, LIMITED
    公开号:EP0897923A1
    公开(公告)日:1999-02-24
    The invention is directed to a benzoquinolizine derivative of the following formula [1], its pharmaceutically acceptable salt, and a pharmaceutical composition comprising the said compound, wherein R1 represents hydroxy or alkoxy; R2 represents hydrogen, hydroxy or alkoxy; R3 represents alkyl; the said alkyl is optionally substituted by hydroxy, alkoxy, amino, monoalkylamino, or dialkylamino; R4 represents alkyl (the said alkyl is optionally substituted by hydroxy or alkoxy), aryl (the said aryl is optionally substituted by alkyl, halogen, hydroxy, alkoxy, amino, monoalkylamino, or dialkylamino), monoalkylamino, or dialkylamino. The compound of the invention has gastrointestinal motility modulating activity and is effective in the treatment of irritable bowel syndrome.
    本发明涉及下式[1]的苯喹嗪衍生物、其药学上可接受的盐以及包含上述化合物的药物组合物、 其中R1代表羟基或烷氧基;R2代表氢、羟基或烷氧基;R3代表烷基;所述烷基可任选被羟基、烷氧基、氨基、单烷基氨基或二烷基氨基取代;R4代表烷基(所述烷基可任选被羟基或烷氧基取代)、芳基(所述芳基可任选被烷基、卤素、羟基、烷氧基、氨基、单烷基氨基或二烷基氨基取代)、单烷基氨基或二烷基氨基。 本发明的化合物具有胃肠道运动调节活性,可有效治疗肠易激综合征。
  • KR1020/200145661
    申请人:——
    公开号:——
    公开(公告)日:——
  • Brossi et al., Helvetica Chimica Acta, 1958, vol. 41, p. 119,129
    作者:Brossi et al.
    DOI:——
    日期:——
查看更多